

**DESCRIPTION**

**Source** Mouse myeloma cell line, NS0-derived mouse TREM2 protein  
Leu19-Ser171, with a C-terminal 6-His tag  
Accession # Q99NH8

**N-terminal Sequence Analysis** Leu19

**Predicted Molecular Mass** 18 kDa

**SPECIFICATIONS**

**SDS-PAGE** 25 - 75 kDa, under reducing conditions.

**Activity** Measured by its ability to bind fluorescein-conjugated *S. aureus* Bioparticles. Daws, M.R. *et al.* (2003) *J. Immunol.* **171**:594. The ED<sub>50</sub> for this effect is 20-120 ng/mL using a His tag antibody coated plate.

**Endotoxin Level** <0.10 EU per 1 µg of the protein by the LAL method.

**Purity** >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

**Formulation** Lyophilized from a 0.2 µm filtered solution in HEPES and NaCl. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

**Reconstitution** Reconstitute at 500 µg/mL in water.


**Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

**DATA**

**Bioactivity**



**Recombinant Mouse TREM2 His-tag Protein Bioactivity**  
Recombinant Mouse TREM-2 (Catalog # 9228-T2) binds fluorescein-conjugated *S. aureus* Bioparticles. The ED<sub>50</sub> for this effect is 20-120 ng/mL using an anti-His tag antibody (Catalog # Catalog # MAB050) coated plate.

**BACKGROUND**

TREM-2 (Triggering Receptor Expressed on Myeloid cells-2) is a 35 kDa type I transmembrane member of the TREM family and Ig superfamily (1). Mature mouse TREM-2 consists of a 153 amino acid (aa) extracellular domain (ECD) with one Ig-like domain, a 21 aa transmembrane segment, and a 35 aa cytoplasmic domain (2). Within the ECD, mouse TREM-2 shares 73% and 90% aa sequence identity with human and rat TREM-2, respectively. Soluble forms of the TREM-2 ECD are generated by alternative splicing or proteolytic cleavage, and the cytoplasmic domain can be liberated by gamma-Secretase mediated intramembrane cleavage (3). A positively charged lysine within the transmembrane segment allows association with the signal adapter protein, DAP12 and inhibition of macrophage activation (4, 5). TREM-2 is expressed on macrophages, immature myeloid dendritic cells, osteoclasts, microglia, and adipocytes (5-9). It promotes the differentiation and function of osteoclasts, the production of inflammatory cytokines by adipocytes, insulin resistance, and the phagocytic clearance of bacteria (9-11). In the CNS, TREM-2 binds to ApoE, ApoA1, and ApoB and mediates the clearance of apoptotic neurons, amyloid plaques, and cell debris following demyelination (6-8, 12). TREM-2 also interacts with and modifies signaling through Plexin A1 on dendritic cells and osteoclasts (13). Mutations in TREM-2 or DAP12 are associated with the development of Alzheimer's disease and Nasu-Hakola disease (NHD/PLOSL) which is characterized by presenile dementia and bone cysts (14, 15). Soluble TREM-2 is elevated in cerebrospinal fluid of patients with active multiple sclerosis (MS), and TREM-2 blockade exacerbates disease symptoms in the experimental EAE model of MS (16, 17).

**References:**

1. Painter, M.M. *et al.* (2015) *Mol. Neurodegener.* **10**:43.
2. Daws, M.R. *et al.* (2001) *Eur. J. Immunol.* **31**:783.
3. Wunderlich, P. *et al.* (2013) *J. Biol. Chem.* **288**:33027.
4. Hamerman, J. A. *et al.* (2006) *J. Immunol.* **177**:2051.
5. Turnbull, I.R. *et al.* (2006) *J. Immunol.* **177**:3520.
6. Takahashi, K. *et al.* (2005) *J. Exp. Med.* **201**:647.
7. Atagi, Y. *et al.* (2015) *J. Biol. Chem.* **290**:26043.
8. Wang, Y. *et al.* (2016) *J. Exp. Med.* **213**:667.
9. Cella, M. *et al.* (2003) *J. Exp. Med.* **198**:645.
10. Park, M. *et al.* (2015) *Diabetes* **64**:117.
11. N'Diaye, E-N. *et al.* (2009) *J. Cell Biol.* **184**:215.
12. Poliani, P.L. *et al.* (2015) *J. Clin. Invest.* **125**:2161.
13. Takegahara, N. *et al.* (2006) *Nat. Cell Biol.* **8**:615.
14. Colonna, M. and Y. Wang (2016) *Nat. Rev. Neurosci.* **17**:201.
15. Paloneva, J. *et al.* (2002) *Am. J. Hum. Genet.* **71**:656.
16. Piccio, L. *et al.* (2008) *Brain* **131**:3081.
17. Piccio, L. *et al.* (2007) *Eur. J. Immunol.* **37**:1290.